RPB-supported researchers at the University of Southern California (USC) report that ranibizumab (sold as Lucentis) can help Hispanic and non-Hispanic whites with diabetic macular edema (DME) in the United States avoid visual impairment and blindness. Diabetic retinopathy and DME are the leading causes of vision loss in working-age adults in the United States.
February 20, 2015
Data from an RPB and MTMVI-supported study showed that while diabetes-related eye diseases doubled since 2014, the most severe forms of the disease have decreased.
Leaders of organizations that fund vision research convened in Washington, D.C. to increase collaboration and maximize the impact of research funding for sight-threatening diseases.
Since 1960, RPB has been transforming vision research and eyecare for the benefit of all people
Maria Bartolomeo Grant, MD, is recognized for ground-breaking contributions to the field of vision research.
The existence of the National Eye Institute, the most important source of funding for vision research in the U.S., is being threatened.
The ARPA-H THEA project takes on an exciting challenge.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |